Introduction {#sec1_1}
============

Advanced malignant biliary obstruction remains a challenging clinical situation for most gastroenterologists since it needs an urgent decision and prompt management. Palliative decompression by biliary drainage is the primary goal when curative resection is no longer feasible due to local invasion and metastasis. For many years, treatment options have been largely depending on endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic biliary drainage (PTBD) \[[@B1], [@B2]\]. Initial ERCP is the standard of care for biliary drainage, while PTBD is usually performed after a failed ERCP procedure. Biliary drainage by ERCP is the first-line option for malignant biliary obstruction and is associated with a lower adverse event rate compare to PTBD \[[@B3]\].

Recently, the introduction of interventional endoscopic ultrasound-guided biliary drainage (EUS-BD) has replace PTBD in many centers worldwide \[[@B4], [@B5], [@B6], [@B7]\]. Meta-analysis showed that EUS-BD is promising as the standard treatment of choice since it is effective and safer than PTBD for biliary drainage when ERCP failed \[[@B8]\]. However, it is not clear whether EUS-BD has a real benefit to the patients in the palliative setting. Pancreatic cancer is the most common cause of biliary obstruction and is still the most lethal cancer in the world. It is often found in advanced state with poor prognosis and lack of satisfying treatment. Therefore, pancreatic malignancy is often a focus of study on biliary drainage management, including cost, risk, benefit, and survival \[[@B9], [@B10]\].

In Indonesia, which is the largest country in Southeast Asia, there have been many developments in the field of endoscopy. Recently, interventional or therapeutic endoscopic ultrasound (EUS) was offered as part of palliative management in patients with malignant biliary obstruction, but there is still debate with regards to the cost and availability issue, especially in more advanced stage of the disease. This study is our first report based on our real clinical practice and experience in a private referral center hospital for hepatopancreatobiliary disorders. The aim of this study was to evaluate the clinical outcomes of EUS-BD in patients with advanced malignant biliary obstruction.

Methods {#sec1_2}
=======

Study Design and Subjects {#sec2_1}
-------------------------

A retrospective (historical cohort) study was done at the Digestive Disease and Gastrointestinal Oncology Center, Medistra Hospital, Jakarta between January 2016 and June 2018. Subjects were selected from adult patients with obstructive jaundice with malignant etiology, indicative for ERCP procedure. PTBD and EUS-BD were performed after ERCP failed cannulation.

All patients underwent initial abdominal imaging studies with ultrasound (US), magnetic resonance cholangiopancreatography, or EUS before the therapeutic procedure was initiated.

Diagnosis of cancer was based on cytopathology examination specimens in patients who agreed to undergo EUS biopsy (fine-needle aspiration \[FNA\]); in patients who did not undergo biopsy it was established by imaging studies (magnetic resonance cholangiopancreatography) combined with significantly increased tumor markers (CA19-9). The result of cytopathology was positive in all cases.

ERCP and PTBD procedures were performed by three senior gastroenterohepatologists; two of them have more than 30 years\' experience (L.A.L., R.A.G.), while the other one has more than 10 years\' experience (C.R.A.L.).

EUS-BD Procedure {#sec2_2}
----------------

EUS-BD was performed by a senior gastroenterohepatologist (C.R.A.L.) who has experience with more than 200 diagnostic EUS procedures and more than 150 EUS-FNA procedures(C.R.A.L.). In most cases the process was supervised by an experienced interventional endosonologist (K.Y.H. or V.D.). The EUS equipment used was an Olympus JF UCT 180 EUS scope which was connected to a high-end US equipment (Aloka IPF-1701C, Tokyo, Japan). The technique used for biliary drainage was EUS-guided choledochoduodenostomy (CDS). A 19-G needle (Echo Tip, Wilson-Cook) is inserted transduodenally into the bile duct under EUS guidance. Bile is aspirated and contrast medium is injected into the bile duct for cholangiography. A 450-cm-long, 0.035-inch guidewire (METII-35-480, Wilson-Cook) was inserted through the 19-G needle into the bile duct. The choledochoduodenal fistula was dilated using a biliary catheter for dilation (Soehendra biliary dilator; Wilson-Cook) or a 6-F cystostome (Endoflex Company). The Hanaro lumen apposing metallic stent was placed through the CDS site into the extrahepatic bile duct.

Technical success refers to successful stent placement in the desired position. Clinical success indicates laboratory improvement of serum bilirubin level, i.e., decreased levels by ≥50% within 2 weeks after the procedure \[[@B11]\].

Data Analysis {#sec2_3}
-------------

Demography and clinical data were presented descriptively. Differences between categorical variables were analyzed using Fisher\'s exact test, while median differences between groups were analyzed using Mann-Whitney U test. Survival difference was tested using Kaplan-Meier survival curve with log-rank *p*. A *p* value \<0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA).

Results {#sec1_3}
=======

Characteristics of the Study Subjects {#sec2_4}
-------------------------------------

Of 144 biliary obstruction cases, there were 38 patients with malignant biliary obstruction enrolled; 24 (63.2%) were male patients. The patients\' mean age was 66.8 ± 12.36 years. The most common etiology of biliary obstruction was pancreatic cancer (44.7%), followed by cholangiocarcinoma and Klatskin tumor. Biliary drainage by ERCP only was achieved in 15 (39.5%) cases. Other characteristics are shown in Table [1](#T1){ref-type="table"}.

Clinical Outcomes after PTBD and EUS-BD {#sec2_5}
---------------------------------------

Technical and clinical success rates were not significantly different between PTBD and EUS-BD (Table [2](#T2){ref-type="table"}). In patients who underwent PTBD, 2 patients with metastatic renal cell carcinoma to the pancreas (Fig. [1](#F1){ref-type="fig"}) and cholangiocarcinoma needed further management with rendezvous technique and internal biliary stent placement. Another 2 patients needed repeated PTBD within 3 days due to failed normalization of bilirubin levels, which were considered clinical failure.

In the EUS-BD group, the only technical failure was a patient who needed salvage percutaneous transhepatic gallbladder drainage (PTGBD) and repeated EUS-BD on the next day due to difficult dilatation of the fistula track (Fig. [2](#F2){ref-type="fig"}). There was no adverse event in patients who underwent PTBD, whereas 1 patient who underwent EUS-BD developed cholangitis and was conservatively managed with antibiotic therapy (Table [3](#T3){ref-type="table"}).

The median survival of patients who underwent PTBD tended to be higher than that of those who underwent EUS-BD (Fig. [3](#F3){ref-type="fig"}). However, metastatic disease tends to be found more frequently in patients undergoing EUS-BD. Furthermore, regardless of the type of procedure, presence of metastasis was the only factor significantly associated with shorter survival (3 vs. 11 months; log-rank *p* = 0.031).

Discussion {#sec1_4}
==========

To our knowledge, this is the first study in Southeast Asia to assess the survival benefit of EUS-BD and PTBD procedures in the management of advanced malignant biliary obstruction as palliative options after ERCP failure, where medical procedural cost is still a major issue. The lower success rate of ERCP in this unit is due to the fact that most of the malignant cases were referred from another hospital with advanced stage of pancreatic cancer or large tumor size causing total distal bile duct obstruction, even though ERCP was performed in the native papilla. In our center, PTBD is routinely performed directly after failed ERCP by consultant gastroenterologists and not by interventional radiologists. Even though we are more experienced in PTBD, EUS-CDS was performed by a senior consultant who was already experienced in diagnostic EUS and EUS-FNA procedures, and most of the procedures were evaluated or supervised by experienced interventional endosonologist.

Currently, EUS-BD is not the first-line management of malignant biliary obstruction in Indonesia or most developing Asian countries. Many studies have shown the advantage of performing EUS-BD after a failed ERCP cannulation \[[@B12], [@B13], [@B14], [@B15]\]. However, EUS-BD requires high levels of experience and technique as most studies were performed in highly expert centers. Furthermore, EUS-BD should be performed in institutions that are capable to do salvage procedures such as PTBD or PTGBD when it fails \[[@B16]\]. In our case series study, the technical success rate of EUS-CDS was quite high (87.5%). The reported technical success rate for EUS-CDS was between 56 and 100% \[[@B13]\]. EUS-CDS was the preferred method in this study because all the patients who underwent either EUS-CDS or PTBD were equally due to distal malignant biliary obstruction. A study involving 101 patients in France concluded that morbidity related to EUS-BD is higher than that related to ERCP, but decreases with an increased learning curve. In their 7-year experience, five procedure-related deaths occurred in the first 50 patients and drop to one in the last 51 patients \[[@B17]\].

Repeated PTBD was needed by only 2 of 15 patients in our study due to clinical failure (decreased bilirubin levels \<50%). After re-intervention, bilirubin levels were much more reduced in both patients. Another patient had metastatic renal cell carcinoma and was managed by PTBD followed by rendezvous technique due to problems with a dislodged catheter and patient discomfort with an external catheter. One patient with ampullary carcinoma underwent common bile duct stenting, but later developed gallbladder empyema which was not related to the stenting procedure. She then underwent PTGBD. Our study is similar to that by Lee et al. \[[@B18]\], who did a randomized trial comparing the impact of EUS-BD with PTBD in advanced distal malignant biliary obstruction. They showed that PTBD has similar efficacy to EUS-BD in advanced disease; however, the authors concluded that complications and re-intervention rates were higher in the PTBD group. In our study experience, we showed almost no significant complications noted in our PTBD group. This result might be different due to the fact that most of PTBD is performed by interventional radiologist in developed Asian countries and even developed Western countries. This issue has also been shown by another two studies where the authors concluded that EUS-BD showed higher clinical success rate and more complications in PTBD group. In the study by Sharaiha et al. \[[@B19]\], it was mentioned that EUS-BD has lower cost than PTBD, but in our country PTBD is much cheaper than EUS-BD \[[@B20]\]. This has been another issue which has to be considered in every country since it would have a big impact on clinical decision regarding the patient\'s survival.

In our patients who underwent EUS-CDS, only 1 patient needed repeated procedure due to technical failure. However, clinical failure occurred in 3 patients; 1 of them died within 10 days after the procedure due to sepsis and renal failure. One patient who developed cholangitis after EUS-BD could be managed conservatively. There was no bile leak, bleeding, or stent migration among our EUS-BD patients.

At this point, it is obvious that technical success and adverse event depends largely on the operator\'s skill. PTBD can be used as a bridge to a rendezvous technique that is commonly used for internal drainage metallic stent placement. The advantages of this procedure are the ease to control bile flow through an external catheter and prevention of clogging stent. However, patient comfort and catheter dislodgment are the two main problems in daily practice. In fact, studies have shown that there is a similar comparable clinical efficacy between PTBD and EUS-BD with regards to the experience in each center \[[@B21], [@B22]\]. However, in most parts of the world, PTBD should be performed by an experienced interventional radiologist. Only in some centers in Asia, including Japan and Indonesia, PTBD was pioneered and developed by interventional hepatologists.

Survival analyses showed that our EUS-BD patients tended to have shorter survival than PTBD patients. However, this could be caused by selection bias since patients who underwent EUS-BD in this study tended to have more severe disease (mostly with metastatic disease) and be of older age. In real practice, this kind of patients may prefer EUS-BD to PTBD for its convenience. Although we are aware of the selection bias, it could not be avoided since patients were not randomized due to patient preference after consent. However, our study results showed the real situation in clinical practice.

Survival benefit was not known, and it assumed that biliary drainage will prolong a patient\'s life. Our previous report showed that pancreatic cancer is the most common cancer referred for EUS imaging \[[@B23]\], and many of the patients were already presented in advanced stage of disease. Metastatic disease might significantly reduce survival regardless of treatment choice. Our current study confirmed that presence of metastasis is the only significant factor to predict survival. Chemotherapy was administered by a medical oncologist based on standard management and indication.

A recent local study from the National Teaching Hospital in Jakarta showed that ERCP has no survival advantage when compared to PTBD in patients with advanced malignant biliary obstruction \[[@B24]\]. This was supported by another study showing that there was a significant increase in inflammatory markers in ERCP patients compared to PTBD patients \[[@B25]\]. The results of these studies were considered to be due to the use of contrast agents in ERCP as the primary cause. On the contrary, in this teaching hospital, PTBD is performed under US guidance, not by fluoroscopy and contrast agent. Procedures involving manipulation of the bile duct and contrast agent filling may increase the risk of epithelial injury and cause bile duct inflammation.

There are some limitations of our study. First, it was not designed as a prospective randomized trial between two groups of patients or a head-to-head comparison study. However, our case series study showed the real-life situation in daily practice. Second, this study might be considered to be underpowered due to the small sample size. However, statistical analyses were not meant to distinguish the efficacy of PTBD versus EUS-BD, since both procedures were known to be equally effective for biliary decompression. Rather, they were performed to give some insight into the clinical performance of the new technique (EUS-BD) over the routine procedure (PTBD). The complexity of the patients with malignant biliary obstruction and ethical considerations did not made it easy to design a head-to-head comparison of EUS-BD and PTBD in the private setting. The reason is because it is probably unethical to do in real-life clinical practice where patients have the right to make a choice after explanation with regards to the stage of the disease.

The role of EUS-BD to replace PTBD or considering it as the primary procedure of choice in advanced malignant biliary obstruction is still questionable since it cannot prolong survival among metastatic pancreatic cancer patients.

In conclusion, advanced malignant biliary obstruction is still a challenging problem in clinical practice. Altogether, the cost, risk, and survival benefit are the most important things to be considered in clinical practice before choosing an option. We suggest that in patients with poor prognosis and possibly distant metastasis, PTBD might be considered the first procedure of choice. However, in cases without metastasis and possibly with better survival with chemotherapy, EUS-BD can be the first choice after failed ERCP cannulation.
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![Patient with metastatic renal cell carcinoma which caused distal biliary obstruction who underwent rendezvous technique (from PTBD) for metallic biliary stent placement.](crg-0013-0385-g01){#F1}

![Pancreatic cancer patient who underwent salvage PTGBD due to the difficulty of fistula track dilatation and repeated EUS-CDS.](crg-0013-0385-g02){#F2}

![Kaplan-Meier survival curves of patients who underwent PTBD and EUS-BD.](crg-0013-0385-g03){#F3}

###### 

Characteristics of the study subjects (*n* = 38)

  Characteristic                                Mean (SD)        *n* (%)
  --------------------------------------------- ---------------- -----------
  Sex                                                            
    Male                                                         24 (63.2)
    Female                                                       14 (36.8)
  Age, years                                    66.8 (12.36)     
  Body mass index, kg/m^2^                      22.3 (3.84)      
  Nutrition status                                               
    Underweight                                                  8 (21.1)
    Normal weight                                                14 (36.8)
    Overweight                                                   9 (23.7)
    Obese                                                        7 (18.4)
  Primary disease                                                
    Pancreatic tumor                                             17 (44.7)
    Cholangiocarcinoma                                           7 (18.4)
    Klatskin tumor                                               4 (10.5)
    Cancer of the ampulla of Vater                               4 (10.5)
    Duodenal cancer                                              2 (5.3)
    Gastric cancer                                               1 (2.6)
    Gallbladder cancer                                           1 (2.6)
    Liver tumor                                                  1 (2.6)
    Renal cancer metastasized to the pancreas                    1 (2.6)
  Total bilirubin, mg/dL                        12.9 (7.80)      
  Direct bilirubin                              11.5 (7.56)      
  Gamma glutaryl transferase, U/L               456.5 (411.48)   
  Alkaline phosphatase, U/L                     360.0 (261.38)   
  Primary procedure                                              
    ERCP                                                         15 (39.5)
    PTBD                                                         15 (39.5)
    EUS-BD                                                       8 (21.1)

###### 

Clinical comparison between patients who underwent PTBD and EUS-BD

  Characteristic                                                           PTBD (*n* = 15)   EUS-BD (*n* = 8)   *p* value
  ------------------------------------------------------------------------ ----------------- ------------------ ----------------------------------------
  Male sex                                                                 9 (60%)           6 (75.0%)          0.657[^a^](#T2F1){ref-type="table-fn"}
  Median age (range)                                                       70 (45--87)       72.5 (44--83)      0.419[^b^](#T2F2){ref-type="table-fn"}
  Pancreatic tumor                                                         7 (46.7%)         6 (75.0%)          0.379[^a^](#T2F1){ref-type="table-fn"}
  Presence of metastatic disease                                           3 (20%)           4 (50%)            0.182[^a^](#T2F1){ref-type="table-fn"}
  Technical success rate                                                   13 (86.7%)        7 (87.5%)          1.000[^a^](#T2F1){ref-type="table-fn"}
  Median bilirubin reduction, % (range)[^d^](#T2F4){ref-type="table-fn"}   76 (34--84)       66 (34--79)        0.119[^b^](#T2F2){ref-type="table-fn"}
  Clinical success rate[^e^](#T2F5){ref-type="table-fn"}                   14 (93.3%)        5 (62.5%)          0.500[^a^](#T2F1){ref-type="table-fn"}
  Median survival, months                                                  11                3                  0.455[^c^](#T2F3){ref-type="table-fn"}

Fisher\'s exact test.

Mann-Whitney U test.

Log-rank test.

Except for 2 cases with increased bilirubin within 2 weeks after procedure.

Includes 1 case after repeated EUS-BD.

###### 

Clinical characteristics of patients who underwent PTBD (*n* = 15) or EUS-BD (*n* = 8)

  Patient No.                       Sex                                  Age, years   Primary tumor        Metastasis   Re-intervention   Survival, months
  --------------------------------- ------------------------------------ ------------ -------------------- ------------ ----------------- ------------------
  *Patients who underwent PTBD*                                                                                                           
  1                                 F                                    73           pancreas             no           Yes               12
  2                                 F                                    76           pancreas             no           no                \<12
  3                                 F                                    76           pancreas             no           no                \<12
  4                                 M                                    48           pancreas             no           no                6
  5                                 F[^1^](#T3F1){ref-type="table-fn"}   65           ampulla of Vater     no           no                8 (alive)
  6                                 M                                    45           pancreas             no           no                \<12
  7                                 M                                    87           duodenal             yes          no                \<6
  8                                 M                                    71           gaster               yes          yes               \<6
  9                                 M                                    51           gallbladder          yes          no                6
  10                                M                                    83           cholangiocarcinoma   no           no                1
  11                                M[^2^](#T3F2){ref-type="table-fn"}   60           kidney               yes          no                1 (alive)
  12                                F                                    56           pancreas             no           no                \<12
  13                                M                                    70           ampulla of Vater     no           no                1
  14                                F                                    79           cholangiocarcinoma   no           no                1
  15                                M                                    55           pancreas             no           no                \<12
                                                                                                                                          
  *Patients who underwent EUS-BD*                                                                                                         
  1                                 F                                    83           pancreas             yes          no                \<3
  2                                 M                                    78           pancreas             no           no                5 (alive)
  3                                 M                                    73           pancreas             yes          no                6
  4                                 F                                    71           pancreas             yes          no                3
  5                                 M[^3^](#T3F3){ref-type="table-fn"}   44           pancreas             no           yes               12
  6                                 M                                    67           duodenal             yes          no                3
  7                                 M                                    72           ampulla of Vater     no           no                \<1
  8                                 M                                    81           pancreas             no           yes               \<1 (alive)

Previously underwent CBD stenting/developed gallbladder empyema → underwent percutaneous transhepatic gallbladder drainage (PTGBD).

Underwent PTBD → rendezvous.

Previously failed EUS-BD then underwent salvage PTGBD → repeated EUS-BD.
